{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:37:52Z","timestamp":1761395872420,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T00:00:00Z","timestamp":1603324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"La ligue contre le cancer","award":["CCIR Est"],"award-info":[{"award-number":["CCIR Est"]}]},{"name":"Idex Universit\u00e9 de Strasbourg","award":["Programme interdisciplnaire"],"award-info":[{"award-number":["Programme interdisciplnaire"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>We describe here the evaluation of the cytotoxic efficacy of two platinum (II) complexes bearing an N-heterocyclic carbene (NHC) ligand, a pyridine ligand and bromide or iodide ligands on a panel of human metastatic cutaneous melanoma cell lines representing different genetic subsets including BRAF-inhibitor-resistant cell lines, namely A375, SK-MEL-28, MeWo, HMCB, A375-R, SK-MEL-5-R and 501MEL-R. Cisplatin and dacarbazine were also studied for comparison purposes. Remarkably, the iodine-labelled Pt-NHC complex strongly inhibited proliferation of all tested melanoma cells after 1-h exposure, likely due to its rapid uptake by melanoma cells. The mechanism of this inhibitory activity involves the formation of DNA double-strand breaks and apoptosis. Considering the intrinsic chemoresistance of metastatic melanoma cells of current systemic treatments, these findings are promising and could give research opportunities in the future to improve the prognosis of patients suffering from unresectable metastatic melanoma that are not eligible or that do not respond to the most effective drugs available to date, namely BRAF inhibitors and the anti-PD-1 monoclonal antibody (mAb).<\/jats:p>","DOI":"10.3390\/ijms21217826","type":"journal-article","created":{"date-parts":[[2020,10,22]],"date-time":"2020-10-22T10:27:58Z","timestamp":1603362478000},"page":"7826","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["In Cellulo Evaluation of the Therapeutic Potential of NHC Platinum Compounds in Metastatic Cutaneous Melanoma"],"prefix":"10.3390","volume":"21","author":[{"given":"Elsa","family":"Charignon","sequence":"first","affiliation":[{"name":"Hospices Civils de Lyon, EA3738-Therapeutic Targeting in Oncology, Universit\u00e9 Jean Monnet-Universit\u00e9 Claude Bernard Lyon1, 165 Chemin du Grand Revoyet, CEDEX, 69921 Oullins, France"},{"name":"INSERM 1052, CNRS 5286, Centre L\u00e9on B\u00e9rard, Centre de Recherche en Canc\u00e9rologie de Lyon, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2707-1290","authenticated-orcid":false,"given":"Mathilde","family":"Bouch\u00e9","sequence":"additional","affiliation":[{"name":"Institut de Physique et Chimie des Mat\u00e9riaux de Strasbourg, Universit\u00e9 de Strasbourg-CNRS UMR7504, Strasbourg, B\u00e2timent 69, 23 Rue du Loess, 67200 Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Clave-Darcissac","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, EA3738-Therapeutic Targeting in Oncology, Universit\u00e9 Jean Monnet-Universit\u00e9 Claude Bernard Lyon1, 165 Chemin du Grand Revoyet, CEDEX, 69921 Oullins, France"},{"name":"H\u00f4pital Nord, D\u00e9partement de Pharmacie, Centre Hospitalier Universitaire de Saint-Etienne, Avenue Albert Raimond, 42270 Saint-Priest, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3284-1472","authenticated-orcid":false,"given":"Georges","family":"Dahm","sequence":"additional","affiliation":[{"name":"Institut de Physique et Chimie des Mat\u00e9riaux de Strasbourg, Universit\u00e9 de Strasbourg-CNRS UMR7504, Strasbourg, B\u00e2timent 69, 23 Rue du Loess, 67200 Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Ichim","sequence":"additional","affiliation":[{"name":"Cancer Cell Death Laboratory, part of LabEx DEVweCAN, Cancer Initiation and Tumoral Cell Identity Department, Centre de Recherche en Canc\u00e9rologie de Lyon, 69008 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Clotagatide","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon, EA3738-Therapeutic Targeting in Oncology, Universit\u00e9 Jean Monnet-Universit\u00e9 Claude Bernard Lyon1, 165 Chemin du Grand Revoyet, CEDEX, 69921 Oullins, France"},{"name":"H\u00f4pital Nord, D\u00e9partement de Pharmacie, Centre Hospitalier Universitaire de Saint-Etienne, Avenue Albert Raimond, 42270 Saint-Priest, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5958-6662","authenticated-orcid":false,"given":"Hichem C.","family":"Mertani","sequence":"additional","affiliation":[{"name":"INSERM 1052, CNRS 5286, Centre L\u00e9on B\u00e9rard, Centre de Recherche en Canc\u00e9rologie de Lyon, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Telouk","sequence":"additional","affiliation":[{"name":"Laboratoire de G\u00e9ologie de Lyon Terre, Plan\u00e8tes, Universit\u00e9 de Lyon, Environnement-ENS-UCBL-CNRS, UMR CNRS 5276 (CNRS, ENS, Universit\u00e9 Lyon1), \u00c9cole Normale Sup\u00e9rieure de Lyon, 9 rue du Vercors, CEDEX 07, 69364 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Caramel","sequence":"additional","affiliation":[{"name":"INSERM 1052, CNRS 5286, Centre L\u00e9on B\u00e9rard, Centre de Recherche en Canc\u00e9rologie de Lyon, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7914-4319","authenticated-orcid":false,"given":"Jean-Jacques","family":"Diaz","sequence":"additional","affiliation":[{"name":"INSERM 1052, CNRS 5286, Centre L\u00e9on B\u00e9rard, Centre de Recherche en Canc\u00e9rologie de Lyon, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9462-5703","authenticated-orcid":false,"given":"St\u00e9phane","family":"Bellemin-Laponnaz","sequence":"additional","affiliation":[{"name":"Institut de Physique et Chimie des Mat\u00e9riaux de Strasbourg, Universit\u00e9 de Strasbourg-CNRS UMR7504, Strasbourg, B\u00e2timent 69, 23 Rue du Loess, 67200 Strasbourg, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-2233","authenticated-orcid":false,"given":"Philippe","family":"Bouvet","sequence":"additional","affiliation":[{"name":"INSERM 1052, CNRS 5286, Centre L\u00e9on B\u00e9rard, Centre de Recherche en Canc\u00e9rologie de Lyon, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France"},{"name":"\u00c9cole Normale Sup\u00e9rieure de Lyon, Universit\u00e9 de Lyon, 9 rue du Vercors, CEDEX 07, 69364 Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-6123","authenticated-orcid":false,"given":"Claire","family":"Billotey","sequence":"additional","affiliation":[{"name":"INSERM 1052, CNRS 5286, Centre L\u00e9on B\u00e9rard, Centre de Recherche en Canc\u00e9rologie de Lyon, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon1, CEDEX 08, 69373 Lyon, France"},{"name":"UFR de M\u00e9decine, Campus Sant\u00e9 Innovations, Universit\u00e9 de Lyon, Universit\u00e9 Jean Monnet, 10 rue de Marandi\u00e8re, 42270 Saint-Priest en Jarez, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e4757","DOI":"10.1136\/bmj.e4757","article-title":"Cutaneous melanoma attributable to sunbed use: Systematic review and meta-analysis","volume":"345","author":"Boniol","year":"2012","journal-title":"BMJ"},{"unstructured":"Stewart, B.W., and Wild, C.P. (2014). World Cancer Report 2014, International Agency for Research on Cancer\/World Health Organization.","key":"ref_2"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/CCO.0b013e32834fca92","article-title":"Resistance patterns with tyrosine kinase inhibitors in melanoma: New insights","volume":"24","author":"Dummer","year":"2012","journal-title":"Curr. Opin. Oncol."},{"key":"ref_4","first-page":"CD011123","article-title":"Systemic treatments for metastatic cutaneous melanoma","volume":"2","author":"Pasquali","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1056\/NEJMc1108651","article-title":"Vemurafenib in melanoma with BRAF V600E mutation","volume":"365","author":"Dalle","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S0140-6736(13)60802-8","article-title":"Cutaneous melanoma","volume":"383","author":"Eggermont","year":"2014","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/bjd.14222","article-title":"Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0\u00b7015% gel: A randomized, controlled 12-month study","volume":"174","author":"Garbe","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"ref_8","first-page":"37","article-title":"Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma","volume":"86","author":"Hamid","year":"2017","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.2147\/OTT.S168313","article-title":"Drug response to PD-1\/PD-L1 blockade: Based on biomarkers","volume":"11","author":"Chen","year":"2018","journal-title":"OncoTargets Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"15042","DOI":"10.1021\/ja075889z","article-title":"Anticancer and antimicrobial metallopharmaceutical agents based on palladium, gold, and silver N-heterocyclic carbene complexes","volume":"129","author":"Ray","year":"2007","journal-title":"J. Am. Chem. Soc."},{"unstructured":"(2020, July 31). N-Heterocyclic Carbene Platinum Complexes: A Big Step Forward for Effective Antitumor Compounds-Bellemin-Laponnaz-2020-European Journal of Inorganic Chemistry-Wiley Online Library. Available online: https:\/\/chemistry-europe.onlinelibrary.wiley.com\/doi\/full\/10.1002\/ejic.201900960.","key":"ref_14"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1021\/jm901693m","article-title":"N-heterocyclic carbene-amine Pt(II) complexes, a new chemical space for the development of platinum-based anticancer drugs","volume":"53","author":"Skander","year":"2010","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7618","DOI":"10.1021\/om300806g","article-title":"Derivatization of Preformed Platinum N-Heterocyclic Carbene Complexes with Amino Acid and Peptide Ligands and Cytotoxic Activities toward Human Cancer Cells","volume":"31","author":"Chardon","year":"2012","journal-title":"Organometallics"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ccr.2016.09.004","article-title":"Update on metal N-heterocyclic carbene complexes as potential anti-tumor metallodrugs","volume":"329","author":"Liu","year":"2016","journal-title":"Coord. Chem. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"15390","DOI":"10.1039\/C6DT02350A","article-title":"Novel cis-[(NHC)1(NHC)2(L)Cl] platinum(II) complexes\u2013synthesis, structures, and anticancer activities","volume":"45","author":"Rehm","year":"2016","journal-title":"Dalton Trans."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1039\/c2nj20928d","article-title":"Au(I)-and Pt(II)-N-heterocyclic carbene complexes with picoline functionalized benzimidazolin-2-ylidene ligands; synthesis, structures, electrochemistry and cytotoxicity studies","volume":"36","author":"Adhikary","year":"2012","journal-title":"New J. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/cr980421n","article-title":"Structure, Recognition, and Processing of Cisplatin-DNA Adducts","volume":"99","author":"Jamieson","year":"1999","journal-title":"Chem. Rev."},{"doi-asserted-by":"crossref","unstructured":"Harlepp, S., Chardon, E., Bouch\u00e9, M., Dahm, G., Maaloum, M., and Bellemin-Laponnaz, S. (2019). N-Heterocyclic Carbene-Platinum Complexes Featuring an Anthracenyl Moiety: Anti-Cancer Activity and DNA Interaction. Int. J. Mol. Sci., 20.","key":"ref_21","DOI":"10.20944\/preprints201907.0215.v1"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/mol.59.4.657","article-title":"Is cisplatin-induced cell death always produced by apoptosis?","volume":"59","author":"Gonzalez","year":"2001","journal-title":"Mol. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0027-5107(01)00111-7","article-title":"Functions of poly (ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death","volume":"477","author":"Herceg","year":"2001","journal-title":"Mutat. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00008390-199902000-00007","article-title":"The chemoresistance of human malignant melanoma: An update","volume":"9","author":"Serrone","year":"1999","journal-title":"Melanoma Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.acr.2017.11.001","article-title":"Bcl-2 Antiapoptotic Family Proteins and Chemoresistance in Cancer","volume":"137","author":"Maji","year":"2018","journal-title":"Adv. Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","article-title":"Molecular mechanisms of resistance and toxicity associated with platinating agents","volume":"33","author":"Rabik","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"ref_27","first-page":"488","article-title":"Treatment of metastatic melanoma: An overview","volume":"23","author":"Bhatia","year":"2009","journal-title":"Oncol. Williston Park N"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8921","DOI":"10.18632\/oncotarget.13475","article-title":"The role of p53 in cancer drug resistance and targeted chemotherapy","volume":"8","author":"Hientz","year":"2017","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.molonc.2011.03.002","article-title":"Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care","volume":"5","author":"Scolyer","year":"2011","journal-title":"Mol. Oncol."},{"key":"ref_30","first-page":"201","article-title":"Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline-Update 2016","volume":"63","author":"Garbe","year":"2016","journal-title":"Eur. J. Cancer Oxf. Engl. 1990"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"120908","DOI":"10.1016\/j.jorganchem.2019.120908","article-title":"Synthesis and structural characterization of benzyl-functionalized N-heterocyclic carbene platinum complexes: Dramatic substituent effect on anti-cancer activity","volume":"899","author":"Dahm","year":"2019","journal-title":"J. Organomet. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by co-targeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ymthe.2016.11.002","article-title":"Systemic Delivery of Tumor-Targeted Bax-Derived Membrane-Active Peptides for the Treatment of Melanoma Tumors in a Humanized SCID Mouse Model","volume":"25","author":"Karageorgis","year":"2017","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.15252\/emmm.201505971","article-title":"ZEB1-mediated melanoma cell plasticity enhances resistance to MAPK inhibitors","volume":"8","author":"Richard","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.molcel.2015.01.018","article-title":"Limited mitochondrial permeabilization causes DNA damage and genomic instability in the absence of cell death","volume":"57","author":"Ichim","year":"2015","journal-title":"Mol. Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.1038\/onc.2010.323","article-title":"Analysis of the genome to personalize therapy for melanoma","volume":"29","author":"Davies","year":"2010","journal-title":"Oncogene"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/21\/7826\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:26:04Z","timestamp":1760178364000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/21\/7826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,22]]},"references-count":36,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2020,11]]}},"alternative-id":["ijms21217826"],"URL":"https:\/\/doi.org\/10.3390\/ijms21217826","relation":{},"ISSN":["1422-0067"],"issn-type":[{"type":"electronic","value":"1422-0067"}],"subject":[],"published":{"date-parts":[[2020,10,22]]}}}